Cesarini, M; Katsanos, K; Papamichael, K; Ellul, P; Lakatos, Péter László; Caprioli, F; Kopylov, U; Tsianos, E; Mantzaris, GJ; Ben-Horin, S; Danese, S; Fiorino, G
(2014)
BACKGROUND: Subjects maintained on infliximab scheduled therapy for inflammatory bowel disease may require dose optimization due to secondary loss of response. There are limited data on infliximab dose optimization for ...